The CCR/KI has a longstanding track record of using mice to study cancer. Over the last decade the Center has successfully generated numerous mouse models that develop tumors that closely resemble the human disease with regard to both the spectrum of contributing mutations and their phenotypic characteristics including progression to the metastatic state. There is now a strong drive by both Kl Scientists and Engineers to use these models to test potential therapeutic strategies and also explore mechanisms of drug resistance. Moreover, these models are a key resource for Kl Engineers, offering in vivo systems to test tumor detection and monitoring devices, drug delivery systems, and chemotherapeutic response. In the current funding period, the Kl has established a new facility, called the Applied Therapeutics &Whole Animal Imaging (ATWAI) Core Facility that exists as a centralized resource to support and encourage these translational efforts. The ATWAI Core developed in two phases. Initially, the Core established the infrastructure necessary to support longitudinal studies of the response and resistance to therapeutic agents, particularly whole animal imaging modalities. This instrumentation has allowed Center members to assess tumor dynamics in vivo including tracking the development and metastasis of tumors and following their response to treatment. Next, in 2008, an expert in mouse models was recruited as Acting Manager of the ATWAI Core with the goal of minimizing the myriad hurdles that exist in setting up and conducting preclinical trials. The ATWAI manager provides Center members with a extensive and customized consultative services, investigator training, and hands-on execution of experiments to enable on-site, high-quality in vivo trials for biosensors, diagnostics, vaccines, chemotherapies, gene therapy, or drug delivery and targeting modalities. Thus, the ATWAI Core helps Center members to bring mouse models to bear on potential therapies, and spurs collaborations between Kl engineers and scientists to allow testing of drug delivery and tumor monitoring systems in appropriate in vivo models. An expansion of the ATWAI Core is planned for the new Koch Institute building, including additional staff and instrumentation. Support from the CCSG is critical to ensure the success of this ATWAI Core, a goal that fits perfectly with the NCI's desire to advance translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014051-42
Application #
8466727
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
42
Fiscal Year
2013
Total Cost
$124,711
Indirect Cost
$88,839
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Lannagan, Tamsin R M; Lee, Young K; Wang, Tongtong et al. (2018) Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. Gut :
Filbin, Mariella G; Tirosh, Itay; Hovestadt, Volker et al. (2018) Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science 360:331-335
Roper, Jatin; Tammela, Tuomas; Akkad, Adam et al. (2018) Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation. Nat Protoc 13:217-234
Suzuki, Hiroshi I; Spengler, Ryan M; Grigelioniene, Giedre et al. (2018) Deconvolution of seed and RNA-binding protein crosstalk in RNAi-based functional genomics. Nat Genet 50:657-661
McKenney, Anna Sophia; Lau, Allison N; Somasundara, Amritha Varshini Hanasoge et al. (2018) JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J Clin Invest 128:789-804
Richardson, Christopher E R; Cunden, Lisa S; Butty, Vincent L et al. (2018) A Method for Selective Depletion of Zn(II) Ions from Complex Biological Media and Evaluation of Cellular Consequences of Zn(II) Deficiency. J Am Chem Soc 140:2413-2416
Choudhury, Atish D; Werner, Lillian; Francini, Edoardo et al. (2018) Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight 3:
Chen, Pan-Yu; Muzumdar, Mandar Deepak; Dorans, Kimberly Judith et al. (2018) Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Res 78:985-1002
Wong, Madeline Y; Chen, Kenny; Antonopoulos, Aristotelis et al. (2018) XBP1s activation can globally remodel N-glycan structure distribution patterns. Proc Natl Acad Sci U S A 115:E10089-E10098
Viswanathan, Srinivas R; Nogueira, Marina F; Buss, Colin G et al. (2018) Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet 50:937-943

Showing the most recent 10 out of 904 publications